




LISTING OF CLAIMS


Claims 1-11 (CANCELED)

- 12- (currently amended) A composition comprising a combination of compound (A) of
5 formula (I), ~~optionally in the form of an optical isomer, or a pharmaceutically acceptable~~
~~salt thereof, and clopidogrel or a pharmaceutically acceptable salt thereof :~~



optionally in the form of an optical isomer, or a pharmaceutically acceptable salt thereof,
and clopidogrel or a pharmaceutically acceptable salt thereof.

- 13- (previously presented) The composition of Claim 12, wherein compound (A) has the (R) configuration.
- 10 14- (previously presented) The composition of Claim 12, wherein compound (A) is in the form of a sodium salt.
- 15- (previously presented) The composition of Claim 12, wherein clopidogrel is in the form of a hydrogen sulphate.
- 15 16- (currently amended) A pharmaceutical composition comprising as active ingredients a combination of compound (A)[[,]] of formula (I) :



optionally in the form of an optical isomer, or a pharmaceutically acceptable salt thereof, and clopidogrel or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable, inert excipients or carriers.

5 17- (currently amended) A pharmaceutical composition of Claim 16, wherein the compound (A) of formula (I) has the (R) configuration.

18- (previously presented) A pharmaceutical composition of Claim 16, wherein compound (A) is in the form of a sodium salt.

10 19- (previously presented) A pharmaceutical composition of Claim 16, wherein clopidogrel is in the form of a hydrogen sulphate.

20- (currently amended) A pharmaceutical composition of Claim 16, wherein the amounts of active ingredients are in the respective ranges of from 1 to 300 mg for the compound (A) of formula (I) and from 10 to 600 mg for clopidogrel.

15 21- (currently amended) A method for treating a cardiovascular ~~illnesses~~ illness involving activation of TP receptors, such method comprising administering to a living animal body, including a human, a therapeutically effective amount of a composition of Claim 12.

20 22- (currently amended) The method of Claim 21, wherein the cardiovascular illness is selected from acute coronary syndrome, stable or unstable angina, endothelial dysfunction, and vascular illnesses ~~associated with atherosclerosis, hypertension, diabetes and heart failure.~~

23- (currently amended) A method for treating ~~or preventing~~ a disorder of the vascular, cardiovascular, or neurovascular system or a thrombo-embolic disorder, such method comprising administering to a living animal body, including a human, a therapeutically effective amount of a composition of Claim 12.

~~22~~ 24 - (currently amended) The method of Claim 23, wherein the thrombo-embolic disorder ~~is associated with~~ results from atherosclerosis, auricular fibrillation and invasive surgical procedures in cardiology, neurology, vascular pathology and/or radiology.